Tags

Type your tag names separated by a space and hit enter

Nonalcoholic steatohepatitis.
Semin Liver Dis. 2004 Feb; 24(1):3-20.SL

Abstract

Nonalcoholic fatty liver disease (NAFLD) is being increasingly recognized as a common liver disorder that represents the hepatic manifestation of the metabolic syndrome, a variably defined aggregate of disorders related to obesity, insulin resistance, type II diabetes, hypertension and hyperlipidemia. Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a risk for progressive fibrosis, cirrhosis, and end-stage liver disease. Hepatocellular carcinoma (HCC) is a documented complication in an as yet unknown percentage of cases of NASH cirrhosis. The diagnosis of nonalcoholic steatohepatitis requires histopathologic evaluation because the lesions of parenchymal injury and fibrosis cannot be detected by imaging studies or laboratory tests. This article will briefly discuss prevalence studies and the pathophysiology of NAFLD and focus on current discussions related to the specific lesions in the pathology of NASH, including the challenges of pediatric NASH and NASH-related cirrhosis.

Authors+Show Affiliations

Saint Louis University Liver Center, Saint Louis University Health Sciences Center, Department of Pathology, St. Louis, Missouri 63110, USA. bruntem@slu.edu

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

15085483

Citation

Brunt, Elizabeth M.. "Nonalcoholic Steatohepatitis." Seminars in Liver Disease, vol. 24, no. 1, 2004, pp. 3-20.
Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis. 2004;24(1):3-20.
Brunt, E. M. (2004). Nonalcoholic steatohepatitis. Seminars in Liver Disease, 24(1), 3-20.
Brunt EM. Nonalcoholic Steatohepatitis. Semin Liver Dis. 2004;24(1):3-20. PubMed PMID: 15085483.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Nonalcoholic steatohepatitis. A1 - Brunt,Elizabeth M, PY - 2004/4/16/pubmed PY - 2004/7/23/medline PY - 2004/4/16/entrez SP - 3 EP - 20 JF - Seminars in liver disease JO - Semin Liver Dis VL - 24 IS - 1 N2 - Nonalcoholic fatty liver disease (NAFLD) is being increasingly recognized as a common liver disorder that represents the hepatic manifestation of the metabolic syndrome, a variably defined aggregate of disorders related to obesity, insulin resistance, type II diabetes, hypertension and hyperlipidemia. Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a risk for progressive fibrosis, cirrhosis, and end-stage liver disease. Hepatocellular carcinoma (HCC) is a documented complication in an as yet unknown percentage of cases of NASH cirrhosis. The diagnosis of nonalcoholic steatohepatitis requires histopathologic evaluation because the lesions of parenchymal injury and fibrosis cannot be detected by imaging studies or laboratory tests. This article will briefly discuss prevalence studies and the pathophysiology of NAFLD and focus on current discussions related to the specific lesions in the pathology of NASH, including the challenges of pediatric NASH and NASH-related cirrhosis. SN - 0272-8087 UR - https://www.unboundmedicine.com/medline/citation/15085483/Nonalcoholic_steatohepatitis_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-2004-823098 DB - PRIME DP - Unbound Medicine ER -